Avalide: Comprehensive Blood Pressure Control in One Tablet
| Product dosage: 162.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.89 | $56.76 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $113.52 $86.00 (24%) | 🛒 Add to cart |
| 90 | $1.27 | $170.28 $114.38 (33%) | 🛒 Add to cart |
| 120 | $1.19 | $227.04 $142.76 (37%) | 🛒 Add to cart |
| 180 | $1.11 | $340.56 $200.38 (41%) | 🛒 Add to cart |
| 270 | $1.06
Best per pill | $510.84 $286.38 (44%) | 🛒 Add to cart |
Synonyms | |||
Avalide combines two proven antihypertensive agents—irbesartan and hydrochlorothiazide—into a single, convenient tablet for effective management of hypertension. This fixed-dose combination therapy targets multiple pathways of blood pressure regulation, offering synergistic effects that often surpass monotherapy outcomes. Designed for patients requiring additional blood pressure control beyond what either component provides alone, Avalide represents a strategic approach in cardiovascular risk management with established efficacy and tolerability profiles in clinical practice.
Features
- Contains irbesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic)
- Available in multiple strength combinations: 150/12.5 mg, 300/12.5 mg, and 300/25 mg
- Once-daily dosing regimen for improved adherence
- FDA-approved for hypertension treatment
- White, biconvex, oval-shaped film-coated tablets
Benefits
- Provides dual-mechanism blood pressure reduction through RAAS inhibition and sodium excretion
- Demonstrates superior efficacy compared to individual components alone
- Offers convenient once-daily dosing that supports long-term treatment adherence
- May reduce cardiovascular morbidity and mortality associated with uncontrolled hypertension
- Minimizes pill burden for patients requiring combination therapy
- Shows favorable metabolic profile in most patient populations
Common use
Avalide is primarily prescribed for the treatment of hypertension in patients for whom monotherapy with either irbesartan or hydrochlorothiazide has proven insufficient. It is particularly valuable for individuals requiring more aggressive blood pressure control to achieve target levels below 130/80 mmHg, as recommended by current hypertension guidelines. The combination is often selected when additional volume control is needed beyond RAAS blockade alone, making it suitable for patients with salt-sensitive hypertension or those who demonstrate an inadequate response to single-agent therapy.
Dosage and direction
The recommended starting dose is Avalide 150/12.5 mg taken orally once daily, preferably in the morning with or without food. dosage may be titrated upward after 2-4 weeks based on blood pressure response. The maximum recommended daily dose is Avalide 300/25 mg. For patients already stabilized on the individual components, the corresponding combination tablet may be substituted. dosage adjustment may be necessary for elderly patients or those with renal impairment, particularly when creatinine clearance falls below 30 mL/min.
Precautions
Periodic monitoring of blood pressure, renal function, and serum electrolytes is recommended, especially during initial titration. Use with caution in patients with impaired hepatic function or progressive liver disease, as minor alterations in fluid and electrolyte balance may precipitate hepatic coma. Monitor for signs of fluid or electrolyte imbalance including hyponatremia, hypochloremic alkalosis, and hypokalemia. Exercise caution in patients with severe congestive heart failure or those taking concomitant medications that affect potassium excretion. Photosensitivity reactions may occur; advise appropriate sun protection.
Contraindications
Avalide is contraindicated in patients with known hypersensitivity to any component of this product or other sulfonamide-derived drugs. Do not use in patients with anuria or severe renal impairment (CrCl <30 mL/min). Contraindicated in pregnancy due to potential for fetal injury and death. Avoid use in patients with refractory hypokalemia, hypercalcemia, or symptomatic hyperuricemia.
Possible side effects
Common adverse reactions (≥2%) include dizziness, fatigue, musculoskeletal pain, nausea/vomiting, and orthostatic hypotension. Less frequent but potentially serious side effects include hyperkalemia, impaired renal function, hypotension in volume-depleted patients, and hypersensitivity reactions including angioedema. Thiazide component may cause glucose intolerance, hyperuricemia, hypochloremia, hyponatremia, and photosensitivity. Rare cases of acute myopia and secondary angle-closure glaucoma have been reported.
Drug interaction
Concurrent use with lithium increases lithium toxicity risk—monitor lithium levels closely. NSAIDs may reduce antihypertensive effect and increase risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to hyperkalemia. Enhanced hypotensive effect when used with other antihypertensives, alcohol, or barbiturates. Corticosteroids and ACTH may intensify electrolyte depletion. Cholestyramine and colestipol may reduce hydrochlorothiazide absorption.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed dose. Maintain regular dosing schedule to ensure consistent blood pressure control. If multiple doses are missed, contact healthcare provider for guidance on resuming therapy.
Overdose
Symptoms may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, and electrolyte disturbances. Management involves supportive care with volume expansion using normal saline for hypotension. Hemodialysis may be effective for irbesartan removal but has limited effect on hydrochlorothiazide elimination. Monitor electrolyte levels and cardiac function continuously. Specific angiotensin II analogs are not available for reversal.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any tablets that appear discolored or damaged.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise clinical judgment when prescribing Avalide, considering individual patient factors, contraindications, and potential drug interactions. Always refer to the complete prescribing information before initiating therapy. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider.
Reviews
Clinical studies demonstrate that Avalide produces significantly greater reductions in systolic and diastolic blood pressure compared to either component alone. In controlled trials, over 70% of patients achieved target blood pressure goals with Avalide therapy. Most patients report satisfactory tolerability with once-daily dosing, though individual experiences may vary. Long-term observational data support maintained efficacy and safety profiles over extended treatment periods. Healthcare providers consistently rate Avalide as an effective option for patients requiring combination antihypertensive therapy.